Uterus News and Research

RSS

Substantial price reduction for 24 Chromosome Aneuploidy Screening

Gene Security Network, Inc. (GSN) today announced a substantial price reduction for its 24 Chromosome Aneuploidy Screening with Parental SupportTM. Effective immediately, pricing has been restructured to a single flat fee for testing of up to 24 embryos in an in vitro fertilization (IVF) cycle.

20 Oct 2009

INVO Bioscience announce the birth of the first baby conceived by the INVO procedure and INVOcell device

INVO Bioscience, Inc., a medical device company focused on treatment options for patients diagnosed with infertility, announced that on September 29, 2009 the birth of the first baby conceived by the INVO procedure and INVOcell device. The mother is a 40 year old Pakistan woman who had suffered from infertility for 16 years.

9 Oct 2009

Uterine artery embolization proves to be better than laparoscopic occlusion of uterine arteries in treating fibroids

BioSphere Medical, Inc. – the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – reports the publication of a study in the October 2009 issue of the Journal of Vascular Interventional Radiology in which the authors conclude that uterine artery embolization (UAE) compares favorably to laparoscopic occlusion of uterine arteries in the treatment of uterine leiomyomas (fibroids) in cases where hysterectomy or myomectomy are not options.

7 Oct 2009

HRT may increase urinary incontinence in postmenopausal women

Grappling with the risks and benefits of hormone replacement therapy (HRT) is nothing new for postmenopausal women. Researchers have now added more fuel to the fire, with evidence that HRT could play a role in incontinence.

7 Oct 2009

Vantia Therapeutics announces the start of Phase II proof-of-concept trials of its VA111913 drug

Vantia Therapeutics today announces that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered Phase II proof-of-concept trials. In addition, Vantia announces results of the successful Phase I trial of VA111913, which showed the product candidate to be safe and well tolerated.

6 Oct 2009

Few risks to babies born to parents who underwent cancer treatment in childhood: Study

Whether they can have children is one of the major concerns for adult survivors of childhood and adolescent cancer because fertility can be compromised by cancer treatment. For cancer survivors who can have children, two new studies led by researchers at Fred Hutchinson Cancer Research Center may help alleviate fears that their childhood disease will adversely impact their newborns.

3 Oct 2009

FDA approves Bayer's IUD Mirena for treating heavy menstrual bleeding

The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.

3 Oct 2009

New molecular imaging technique raises hope for common malignant female tumor

A promising new molecular imaging technique may provide physicians and patients with a noninvasive way to learn more information about a type of cancer of the uterus lining called "endometrial carcinoma"-one of the most common malignant female tumors. This research was presented in a study published in the October issue of The Journal of Nuclear Medicine.

1 Oct 2009

Latest optical and laser technology in medicine displayed at FiO meeting

From scopes that help premature babies breathe to techniques for imaging live neurons and beating hearts as they develop, the latest optical and laser technology being deployed in medicine and the biosciences will be on display at the Optical Society's (OSA) Annual Meeting, Frontiers in Optics (FiO), which takes place Oct. 11-15 at the Fairmont San Jose Hotel and the Sainte Claire Hotel in San Jose, Calif.

1 Oct 2009

New device could be the solution to menstrual pain

While most women experience minor pain during menstruation, for others, the pain can be severe enough to interfere with everyday activities and require medication. New research to be presented at the 2009 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will reveal initial findings of safety surrounding a new device that may more effectively treat menstrual pain.

22 Sep 2009

Mayo Clinic Women's HealthSource discusses myths and facts about ovarian cancer

But not all the news about ovarian cancer is grim. Incidence is declining. Doctors are learning more about early symptoms and more effective treatments. The September issue of Mayo Clinic Women's HealthSource looks at myths and facts about ovarian cancer.

17 Sep 2009

Quatrx' second phase 3 study of ospemifene tablets provides positive results

QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study for Ophena(TM) (ospemifene tablets), the company's investigational compound in development for the treatment of postmenopausal vulvovaginal atrophy (VVA).

10 Sep 2009

80 percent residents aware of family building options: RESOLVE survey

According to a recent survey conducted by RESOLVE: The National Infertility Association (RESOLVE), Washington, D.C. metro-area residents are highly aware of various family building options due to a patient’s infertility diagnosis, such as medical treatment, adoption and surrogacy.

10 Sep 2009

Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice

Nanoparticle delivery of diphtheria toxin-encoding DNA that expresses selectively in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect that this therapy could be tested in humans with advanced ovarian cancer within 18 to 24 months, according to a report in Cancer Research. If additional tests are successful, these finding could lead to a new treatment for ovarian cancer, which now causes more than 15,000 deaths each year in the United States. Because it is usually diagnosed at a relatively late stage, ovarian cancer is one of the most deadly forms of the disease.

7 Sep 2009

Angiotensin II receptors not detectable in pregnant or preeclamptic women

A new study by researchers at Wake Forest University School of Medicine reveals a key component in the development of preeclampsia in pregnant women, a condition that can result in miscarriage and maternal death.

5 Sep 2009

New car design for pregnant mothers

UK researchers have developed a new computer model - Expecting - that can be used as a design tool for automotive designers to help ensure that vehicle designs can accommodate the safety needs of pregnant occupants.

3 Sep 2009

Nonsurgical, quick and accurate test for diagnosing endometriosis discovered

A quick and accurate test for endometriosis that does not require surgery has been developed by researchers from Australia, Jordan and Belgium, according to new research published online today (Wednesday 19 August) in Europe's leading reproductive medicine journal Human Reproduction.

19 Aug 2009